viewApricus Biosciences Inc

Apricus Biosciences Receives Patent In Japan For Sexual Dysfunction Treatment


Apricus Biosciences (NASDAQ:APRI) said on Friday the Japanese Patent Office has granted it a patent for its use of a vasoactive prostaglandin E, a hormone compound, to treat premature ejaculation.

 “We are very pleased with this patent allowance in Japan for the use of vasoactive prostaglandin E to treat premature ejaculation, which includes the same pharmaceutical composition as Vitaros, combined with a local anesthetic,” said Bassam Damaj, CEO of Apricus.

Vitaros is the company’s erectile dysfunction topical cream which has been approved in Canada.  Like Vitaros, the premature ejaculation treatment will also be a topical cream formulation. 

To date, Apricus has completed two single-blind studies and one double-blind study for the application of vasoactive prostaglandin E to treat premature ejaculation. 

The patent, when issued, will last until March 2024. Besides the patent announced today, the company's premature ejaculation treatment has also received patents in Australia and Singapore.   There are an additional nine applications pending.

Apricus, based in East Windsor, New Jersey, is a biopharmaceutical company that develops drugs in the areas of cancer, sexual dysfunction, and inflammation.  

Since the announcement, the company’s shares have rallied roughly 3.7% to trade at $3.96 as of 1:23 pm EST.

Quick facts: Apricus Biosciences Inc

Price: - -

Market: NASDAQ
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Fertoz continues to plan for the future despite extremely...

Fertoz Ltd (ASX: FTZ) Executive Chairman Patrick Avery joined Steve Darling from Proactive Vancouver on Skype to discuss what has been a very tough weather year for the company. Even with that, Avery says the company has been very busy this year signing a number of distribution...

1 day, 6 hours ago

2 min read